Genmab A/S Sponsored ADR (NASDAQ:GMAB) Short Interest Update

Key Points

• Short interest in Genmab A/S increased by 109.1% in July, with a total of 3,660,000 shares, indicating a significant rise in bearish sentiment around the stock.
• The company reported an earnings per share of $0.31 for the last quarter, exceeding analysts' expectations of $0.23, despite having revenue below estimates at $715 million.
• Several brokerages have upgraded Genmab A/S's rating to "buy," with a consensus target price of $37.80, indicating confidence in the company's future performance.

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totaling 3,660,000 shares, anincreaseof109.1% from the June 30th total of 1,750,000 shares. Based on an average daily volume of 1,400,000 shares, the short-interest ratio is currently 2.6 days. Currently,0.6% of the shares of the company are short sold. Currently,0.6% of the shares of the company are short sold. Based on an average daily volume of 1,400,000 shares, the short-interest ratio is currently 2.6 days.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on GMAB shares. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday, July 28th. Truist Financial increased their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday, July 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $37.80.

Institutional Trading of Genmab A/S

Several large investors have recently made changes to their positions in the company. Sei Investments Co. boosted its stake in Genmab A/S by 55.2% during the 4th quarter. Sei Investments Co. now owns 57,702 shares of the company's stock valued at $1,205,000 after purchasing an additional 20,525 shares during the last quarter. LPL Financial LLC boosted its stake in shares of Genmab A/S by 3.3% in the 4th quarter. LPL Financial LLC now owns 195,436 shares of the company's stock worth $4,079,000 after buying an additional 6,288 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Genmab A/S by 3,049.3% in the 4th quarter. JPMorgan Chase & Co. now owns 407,613 shares of the company's stock worth $8,507,000 after buying an additional 394,670 shares during the last quarter. Franklin Resources Inc. boosted its stake in shares of Genmab A/S by 20.4% in the 4th quarter. Franklin Resources Inc. now owns 30,896 shares of the company's stock worth $645,000 after buying an additional 5,233 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of Genmab A/S by 18,959.1% in the 4th quarter. Russell Investments Group Ltd. now owns 510,784 shares of the company's stock worth $10,660,000 after buying an additional 508,104 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

Shares of GMAB stock traded down $1.26 during mid-day trading on Friday, hitting $21.43. The company's stock had a trading volume of 1,745,722 shares, compared to its average volume of 1,084,945. The company's fifty day simple moving average is $21.74 and its 200-day simple moving average is $20.86. Genmab A/S has a 52 week low of $17.24 and a 52 week high of $27.94. The company has a market cap of $13.75 billion, a PE ratio of 10.77, a P/E/G ratio of 6.89 and a beta of 0.95.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.39 by $0.15. The company had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a return on equity of 21.23% and a net margin of 37.53%. On average, equities analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.